Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function.

Department of Laboratory Medicine, University of California, San Francisco, CA 94142, USA.
Journal of Thrombosis and Haemostasis (Impact Factor: 5.55). 03/2006; 4(2):436-42. DOI: 10.1111/j.1538-7836.2006.01744.x
Source: PubMed

ABSTRACT The platelet fibrinogen receptor, a heterodimer consisting of integrin subunits alpha(IIb) and beta(3), is required for platelet aggregation, spreading, and hemostasis. Platelet agonists such as thrombin and adenosine diphosphate (ADP) lead to the activation of alpha(IIb)beta(3), thereby enhancing its affinity and avidity for binding fibrinogen (inside-out signaling). Furthermore, fibrinogen binding to alpha(IIb)beta(3) triggers cytoskeletal changes and granule release (outside-in signaling).
Genetic approaches to characterize the molecular pathways involved in alpha(IIb)beta(3) signaling are not possible with anucleate blood platelets. Therefore, we have established an OP9 stromal cell co-culture system to generate megakaryocytes from human embryonic stem cells (hESCs).
alpha(IIb)beta(3) activation, measured by soluble fibrinogen binding to hESC-derived megakaryocytes, /GPIbalpha(+) cells, is readily detectable following stimulation with known platelet agonists. Dose-response curves for peptide agonists specific for the two platelet thrombin receptors, protease-activated receptor 1 (PAR1) and PAR4, show a relative responsiveness that mirrors that of human platelets, and sub-maximal ADP responses are augmented by epinephrine. Moreover, hESC-derived megakaryocytes undergo lamellipodia formation, actin filament assembly, and vinculin localization at focal adhesions when plated on a fibrinogen-coated surface, characteristic of alpha(IIb)beta(3) outside-in signaling. Undifferentiated hESCs genetically modified by lentiviral infection can be cloned and maintained in an undifferentiated state and then differentiated into megakaryocytes capable of alpha(IIb)beta(3) activation.
Using hESCs, we have developed a renewable source of human megakaryocytes, and a genetically tractable system for studying megakaryocytopoiesis and alpha(IIb)beta(3) signaling in the native cellular environment.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Megakaryocyte-specific transgene expression in patient-derived induced pluripotent stem (iPS) cells offers a new approach to study and potentially treat disorders affecting megakaryocytes and platelets. Using a Gp1ba promoter, we have developed a strategy to achieve a high level of protein expression in human megakaryocytes. The feasibility of this approach was demonstrated in iPS cells derived from two patients with Glanzmann thrombasthenia (GT), an inherited platelet disorder caused by mutations in integrin αIIbβ3. Hemizygous insertion of Gp1ba promoter-driven human αIIb cDNA into the AAVS1 locus of iPS cells lead to high αIIb mRNA and protein expression, and correction of surface αIIbβ3 in megakaryocytes. Agonist stimulation of these cells displayed recovery of integrin αIIbβ3 activation. Our findings demonstrate a novel approach to studying human megakaryocyte biology as well as functional correction of the GT defect, offering a potential therapeutic strategy for patients with diseases that affect platelet function.
    Blood 12/2013; · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Platelets for transfusion, obtained from volunteer blood donors are a limited resource. Given the increased range of donor restrictions to prevent transmission of disease and the decline in volunteer blood donors there is a diminishing pool of blood for transfusion. Production of mature blood cells from hematopoietic stem cells (HSCs) via large-scale manufacture is an alternative way of meeting transfusion demands. In this review we provide a detailed outline of the challenges and opportunities for the bio-manufacture of platelets. We describe the scale required for platelet bio-manufacture to deliver sufficient cells for transfusion, a brief outline of the current understanding of megakaryopoiesis and thrombogenesis and highlight how this impacts on the design of culture systems and bioreactors for producing platelets.
    Experimental hematology 03/2014; · 3.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hematopoietic stem cells (HSCs) are defined by their capacity to self-renew and to differentiate into all blood cell lineages while retaining robust capacity to regenerate hematopoiesis. Based on these characteristics, they are widely used for transplantation and gene therapy. However, the dose of HSCs available for use in treatments is limited. Therefore, extensive work has been undertaken to expand HSCs in culture and to produce HSCs from embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) in order to improve the efficiency and outcome of HSC-based therapies. Various surface markers have been characterized to improve the purification of HSCs and a huge number of cytokines and small-molecule compounds have been screened for use in the expansion of HSCs. In addition, attempts to generate not only HSCs but also mature blood cells from ESCs and iPSCs are currently ongoing. This review covers recent approaches for the purification, expansion or production of human HSCs and provides insight into problems that need to be resolved. Anat Rec, 2013. © 2013 Wiley Periodicals, Inc.
    The Anatomical Record Advances in Integrative Anatomy and Evolutionary Biology 12/2013; · 1.34 Impact Factor

Full-text (2 Sources)

1 Download
Available from
Jan 28, 2015